Cargando…

An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% (w/v) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival

Purpose: To examine the physicochemical properties of five preservative-free (PF) 0.005% latanoprost ophthalmic products; Monoprost(®), Latanest(®), Gaap Ofteno(®), Xalmono(®), and Xaloptic(®) Free. Furthermore, the study investigated the mucin production and cell survival of primary cultured human...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freiberg, Josefine C., Hedengran, Anne, Heegaard, Steffen, Petrovski, Goran, Jacobsen, Jette, Cvenkel, Barbara, Kolko, Miriam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181163/ https://www.ncbi.nlm.nih.gov/pubmed/35683527 http://dx.doi.org/10.3390/jcm11113137

Ejemplares similares

Impact of benzalkonium chloride-preserved and preservative-free latanoprost eye drops on cultured human conjunctival goblet cells upon acute exposure and differences in physicochemical properties of the eye drops
por: Müllertz, Olivia, et al.
Publicado: (2021)

Generic benzalkonium chloride‐preserved travoprost eye drops are not identical to the branded polyquarternium‐1‐preserved travoprost eye drop: Effect on cultured human conjunctival goblet cells and their physicochemical properties
por: Hedengran, Anne, et al.
Publicado: (2022)

Comparing the effect of benzalkonium chloride-preserved, polyquad-preserved, and preservative-free prostaglandin analogue eye drops on cultured human conjunctival goblet cells
por: Hedengran, Anne, et al.
Publicado: (2024)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue, Kenji, et al.
Publicado: (2012)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Nakakura, Shunsuke, et al.
Publicado: (2012)

IL‐4 and IL‐13 both contribute to the homeostasis of human conjunctival goblet cells in vitro
por: Hansen, Pernille M., et al.
Publicado: (2022)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
por: Paolera, Mauricio D, et al.
Publicado: (2008)

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
por: Radcliffe, Nathan, et al.
Publicado: (2020)

Noninferiority Study Comparing Latanoprost 0.005% Without Versus With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension
por: Wirta, David, et al.
Publicado: (2022)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Özkurt, Yelda Buyru, et al.
Publicado: (2009)

A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
por: Weinreb, Robert N, et al.
Publicado: (2015)

Open-Label Extension Study Comparing Latanoprost 0.005% Without vs With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension
por: Shen Lee, Bridgitte, et al.
Publicado: (2022)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
por: Inoue, Kenji, et al.
Publicado: (2014)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: Godfrey, David A, et al.
Publicado: (2009)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

Intraocular Pressure Reduction Effect of 0.005% Latanoprost Eye Drops in a Hyaluronic Acid-Chitosan Nanoparticle Drug Delivery System in Albino Rabbits
por: Rubenicia, Ana Marie L., et al.
Publicado: (2021)

Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma
por: Hagras, Sherein M, et al.
Publicado: (2021)

Retract p < 0.005 and propose using JASP, instead
por: Perezgonzalez, Jose D., et al.
Publicado: (2018)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

The assessment of intrinsic credibility and a new argument for p < 0.005
por: Held, Leonhard
Publicado: (2019)

Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan(®) and Arulatan(®)) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial
por: Brant Fernandes, Rodrigo A, et al.
Publicado: (2019)

Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
por: Inoue, Kenji, et al.
Publicado: (2012)

A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study
por: Walters, Thomas R., et al.
Publicado: (2022)

Early Effect of 0.005% Estriol Vaginal Gel on Symptoms and Signs of Vulvovaginal Atrophy
por: Lázaro-Carrasco de la Fuente, Jesús, et al.
Publicado: (2022)

Novel Approaches to Optimize Treatment Strategies in Glaucoma
por: Kolko, Miriam, et al.
Publicado: (2021)

Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
por: Molinelli, Elisa, et al.
Publicado: (2020)

Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride
por: Wong, Tina T, et al.
Publicado: (2018)

In vivo fluorescence imaging of conjunctival goblet cells
por: Kim, Seonghan, et al.
Publicado: (2019)

Modulation of Conjunctival Goblet Cell Function by Inflammatory Cytokines
por: Contreras-Ruiz, L., et al.
Publicado: (2013)

The protective role of conjunctival goblet cell mucin sialylation
por: Matsuzawa, Moe, et al.
Publicado: (2023)

The temperature stability of 0.005°C for the concrete floor in the CERN Transfer Tunnel #1 hosting the Precision Laser Inclinometer
por: Azaryan, N, et al.
Publicado: (2017)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2012)

Garnet-Based All-Ceramic Lithium Battery Enabled by Li(2.985)B(0.005)OCl Solder
por: Feng, Wuliang, et al.
Publicado: (2020)

Trifarotene 0.005% Cream in the Treatment of Facial and Truncal Acne Vulgaris in Patients with Skin of Color: a Case Series
por: Del Rosso, James Q., et al.
Publicado: (2022)

Sodium Hypochlorite 0.005% Versus Placebo in the Treatment of Mild to Moderate Acne: A Double-Blind Randomized Controlled Trial
por: Dorostkar, Azadeh, et al.
Publicado: (2021)

Plague mitigation for prairie dog and black-footed ferret conservation: Degree and duration of flea control with 0.005% fipronil grain bait
por: Eads, David A., et al.
Publicado: (2023)

Effect of topical rebamipide on conjunctival goblet cell recovery after vitrectomy
por: Kato, Kumiko, et al.
Publicado: (2016)

Immunomodulatory Cross-Talk between Conjunctival Goblet Cells and Dendritic Cells
por: Contreras-Ruiz, Laura, et al.
Publicado: (2015)

Context-Dependent Regulation of Conjunctival Goblet Cell Function by Allergic Mediators
por: García-Posadas, Laura, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6e0duumcpkq9cns3l2gmf2g8pv